Medical device outsourcing company Vention Medical has acquired ATEK Medical Group, a leader in medical device assembly, packaging and injection moulding.

Dan Croteau, CEO of Vention Medical, said, “Our partnership with the ATEK Medical Group management team will allow Vention to provide an enhanced customer experience. Like Vention, ATEK Medical Group aspires to continually satisfy customers through intense focus on services that improve quality, innovation, and cost.”

The acquisition will incur a variety of combined capabilities and services, including product design and development, innovative component technologies, along with the manufacturing space of 175,000 square feet at its Costa Rica campus.

ATEK recently opened a second facility in Grand Rapids, Michigan, to support customer demands in the US.

Chris Oleksy, President of ATEK Medical, and Tom Houdeshell of ATEK Plastics, said that Vention’s experience and capabilities in design, components and assembly makes Vention “a very appealing partner for us”.

Vention Medical specialises in components and services used in interventional and minimally-invasive products, including medical balloons, advanced extrusions and heat shrink tubing, clean room injection moulding, assembly and packaging services.

Nycomed, a Takeda company, has appointed Jostein Davidsen as its new Head of Emerging Markets.

Mr Davidsen will take on the post in addition to his current role as Area Head of Russia/CIS, reporting to Frank Morich, EVP, International Operations at Takeda Pharmaceuticals International, and CEO of Nycomed.

“Jostein's strong track record of leading Russia/CIS over the past 17 years makes him an ideal candidate for this position,” said Mr Morich.

“His extensive knowledge of the industry, combined with vision and tenacity, has propelled Russia/CIS to become one of Nycomed's top revenue contributors.”

Takeda’s acquisition of Nycomed in September 2011 was driven by Nycomed’s presence in Emerging Markets in Russia/CIS, Latin America, Middle East-Turkey-Africa and South Asia.

Takeda is a research-based global company with a main focus on pharmaceuticals. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Takeda Pharmaceutical Company has acquired Nycomed in a deal worth €9.6 million on a cash-free, debt-free basis.

The combined company will be commercially active in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Current Takeda Executive Vice President of International Operations, Dr Frank Morich, has been appointed as CEO of Nycomed.

Yasuchika Hasegawa, President and CEO of Takeda, said: “Partnering the two organisations will have complementary effects and further increase our potential to become a truly global pharmaceutical company.”

Dr Morich said that the combined company’s pharmaceutical market will cover more than 70 countries, with a presence in Japan, North America, Europe and Asia.

“I look forward to bringing Takeda and Nycomed together to ensure we can achieve enhanced revenue, growth and diversification, while maintaining the strong momentum of both companies,” he said.